EDGAR·FLOW

Aprea Therapeutics, Inc. — Form 8-K

Filed November 20, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Aprea announced interim Phase 1 results for APR-1051 (WEE1 inhibitor) in 56 patients with advanced solid tumors as of November 1, 2026. Key findings: 1 confirmed partial response (PR) and 1 unconfirmed PR in PPP2R1A-mutated uterine cancer patients; 5 patients with stable disease >4 months; 84% of evaluable patients (21/25) showed ≥50% reduction in pCDK1-Y15 (WEE1 target engagement); 1 dose-limiting toxicity (liver enzyme elevation at 50mg); predominantly Grade 1-2 adverse events. Company plans to enroll ≥50 additional patients in focused cohorts (uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer), with dose escalation completion expected Q2 2027.
Why this rating

Early clinical proof-of-concept with confirmed PR in lead program is material for $8.6M-cap biotech; validates WEE1 target biology, supports continued development. Safety/PK favorable. Meaningful near-term catalyst.

Tradability signal
NO TRADE

No trade: price $0.41 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$0.52 ▲ 15.81%
at our read · unknown
$0.45
+10 min · unknown
$0.41 ▼ 8.69%
+30 min · unknown
$0.33 ▼ 25.41%
+1 hr · unknown
$0.27 ▼ 39.71%
+4 hrs · unknown
$0.23 ▼ 47.75%

The stock had already moved -13.65% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ APRE · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.